Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer

Summary

This phase I/II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of patients with metastatic cancer and symptoms of anxiety and/or depression. Psilocybin is a substance being studied in conjunction with therapy for the treatment of anxiety and depression in patients with cancer. In this study, the psilocybin being used is derived from the mushroom psilocybe cubensis using a patented process that results in a pharmaceutical grade version of psilocybin. Psilocybin acts by activating serotonin receptors on brain cells which can change perceptions and patterns of thinking in ways that may decrease anxiety.

Timeline

Start

2023-06-27

Primary completion

2024-04-08

Completion

2024-10-17

Publications

• Back A, Myers S, Guy J, Perez J, Lazar Thorn L, McGregor B. Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy. Psychedelic Med (New Rochelle). 2024 Dec 2;2(4):187-191. doi: 10.1089/psymed.2023.0069. eCollection 2024 Dec.

Drugs

Indications